Melin­ta will beef up its an­tibi­otics pipeline af­ter a merg­er with trou­bled Cem­pra

Just weeks af­ter Melin­ta Ther­a­peu­tics com­plet­ed an R&D odyssey with an FDA ap­proval for the an­tibi­ot­ic de­lafloxacin (Baxdela), the biotech has struck a deal to merge trou­bled Cem­pra $CEMP in­to the com­pa­ny, tak­ing over its an­tibi­otics pipeline and one ap­proved ther­a­py.

Melin­ta in­vestors  — who come out of the deal with a pub­lic list­ing on Nas­daq — will wind up just bare­ly on top, with 52% of the shares in the com­bined op­er­a­tion, which re­tains the Melin­ta name.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.